Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

Contentful, a leading content platform trusted by more than 4,200 customers, today launched a host of new features and partnerships that ? together with Contenful's market-leading content management ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

New AI and personalization capabilities extend company’s core CMS offering, delivering a flexible, future-fit solution for brands to create and manage compelling digital experiences DENVER & ...